Cronos stock climbs after launching Peace Naturals medical cannabis brand in Germany
The U.S.-listed shares of Cronos Group Inc. (CRON.T) climbed 2.5% in premarket trading Monday, after the Toronto-based cannabis company said it launched its Peace Naturals medical brand in Germany. The company has signed a distribution agreement with Cansativa Group, which has a network of about 2,000 pharmacies in Germany. Cronos said it expects the recently announced regulatory changes in Germany, in which cannabis is no longer labeled a narcotic, to "unlock significant growth" in Germany. "Re-entering the German market, which has about 83 million people, is a significant milestone for Cronos and we look forward to expanding our reach and brand awareness in Germany with the help of Cansativa," said Cronos Chief Executive Mike Gorenstein. The stock has soared 39.8% over the past three months through Friday, while the AdvisorShares Pure US Cannabis ETF (MSOS) has jumped 65.5% and the S&P 500 has gained 0.9%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-18-23 0747ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst